Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Dance Biopharm forms joint venture with Harmony Asset for inhaled insulin

Oct. 18, 2013

Phase II results presented for blosozumab, a monoclonal antibody targeting sclerostin

Oct. 18, 2013

FDA committee votes against approval of Vascepa

Oct. 17, 2013

Phase III alirocumab results show efficacy superior to ezetimibe

Oct. 17, 2013

Hanmi Pharmaceutical advances new biological drug for diabetes to phase IIb trials

Oct. 17, 2013

Discovery of novel EP4 agonists reported by Cayman Chemical Company, Myometrics

Oct. 17, 2013

Boehringer Ingelheim and Lilly submit application in Japan for empagliflozin

Oct. 15, 2013

MannKind resubmits Afrezza NDA

Oct. 15, 2013

Protalix BioTherapeutics reports phase I data for PRX-112

Oct. 15, 2013

Takeda Pharmaceutical prepares novel GL-R antagonists for diabetes

Oct. 15, 2013

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...